Fractyl Health, Inc. (GUTS)
| Market Cap | 103.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -140.95M |
| Shares Out | 158.65M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,103,244 |
| Open | 0.659 |
| Previous Close | 0.653 |
| Day's Range | 0.640 - 0.665 |
| 52-Week Range | 0.377 - 3.030 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 5.40 (+726.45%) |
| Earnings Date | May 13, 2026 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably alteri... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GUTS stock is "Strong Buy." The 12-month stock price target is $5.4, which is an increase of 726.45% from the latest price.
News
Fractyl Health Earnings Call Transcript: Q4 2025
Revita's pivotal study is fully enrolled and on track for key data readouts in 2026, with strong clinical, regulatory, and commercial momentum. Financial discipline extends runway into 2027, and no capital raise is planned before pivotal data.
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat...
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti...
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.
Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product
Fractyl Health Inc. (NASDAQ: GUTS) stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita.
Fractyl Health Transcript: Study result
Six-month data from the REMAIN-1 pilot show Revita significantly reduces post-GLP-1 weight regain, especially in high-risk patients, with strong safety and metabolic benefits. The pivotal study is fully enrolled and on track for top-line data and potential FDA submission in late 2026.
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolera...
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that trea...
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approxima...
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking approache...
Fractyl Health Transcript: Evercore ISI 8th Annual HealthCONx Conference
Revita, an endoscopic procedure, demonstrates strong potential to curb post-GLP-1 weight regain, with six-month data showing minimal weight rebound and stable glucose control. Key randomized and pivotal trial results are expected in 2024 and 2026, supporting regulatory filings.
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat ro...
Fractyl Health Earnings Call Transcript: Q3 2025
Revita demonstrated sustained weight loss after GLP-1 discontinuation, with pivotal trials progressing ahead of schedule and strong durability shown in real-world data. Financials remain robust, supporting key milestones into early 2027.
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-lab...
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes...
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the po...
Fractyl Health Transcript: Study Update
The REMAIN-1 midpoint cohort showed that Revita significantly prevented weight regain three months after GLP-1 discontinuation, with a 12.5% treatment difference versus sham and a strong safety profile. These results support Revita as a potential scalable, durable therapy for post-GLP-1 weight maintenance, with pivotal data and regulatory milestones expected in 2026.
Fractyl Health says experimental procedure helps maintain weight-loss in study
Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “F...
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regai...
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors
Fractyl Health Transcript: Canaccord Genuity’s 45th Annual Growth Conference
The company is advancing Revita, a device-based gut procedure for durable post-GLP-1 weight maintenance, with pivotal trial data expected soon and strong early results. A gene therapy platform, Rejuva, aims for lifelong diabetes and obesity remission, with clinical trials starting next year.
Fractyl Health Earnings Call Transcript: Q2 2025
Q2 2025 saw strong progress in clinical milestones, a $23M capital raise, and reduced cash burn. Revita showed durable weight maintenance, with pivotal data readouts ahead, while Rejuva advanced toward clinical trials. Cash runway extends into 2026.
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation; in...